文摘
摘要目的:开发一个完全自动化的,(负责人)分析管道高通量白质高密度临床fluid-attenuated反转恢复(天赋)图像。
背景:研究负责人卷(WMHv)是一个重要的和高度遗传性脑血管表型,这是急性缺血性中风的风险和结果密切相关(AIS)。遗传学可以援助负责人生物学的理解;然而,大规模的基因研究的负责人AIS患者因为手动或半自动方法临床MRI扫描,需要一个高通量,全自动WMHv分析管道临床天赋图像。
设计/方法:每个病人的天赋图像首先upsampled使用bi-cubic插值来减少各向异性体素的大小的影响。随后,parameter-free大脑提取使用健壮的大脑执行提取。所有图片然后注册一个内部才能使用先进的标准化工具模板。执行自动化的研究负责人识别和描述leukoaraiosis使用主成分分析模式,从100年手动分割。从non-interpolated WMHv计算为每个主题片。两分的手工分割评估变化通过计算标准差(SD) WMHv(9主题;6各评级机构)。好自动和手动轮廓之间的协议是358年评估对象(内自动WMHv 3 sd手工WMHv)。
结果:WMHv计算一组2703天赋的图片来自12个独立的AIS患者组(网站)的一部分核磁共振成像- - - - - -创etic我nterfaceExploration (MRI-GENIE)研究。我们观察到的对数转换分布为每个站点WMHv大约是高斯。协议之间的手动和自动分割显示,88%的自动WMHv属于3从手工WMHv SD,显示良好的协议。
结论:使用全自动WMHv临床核磁共振成像分析管道既可行又显示了良好的协议手册概述了。重要的是,进一步分析提取的WMHv有可能推进当前的知识在AIS和结果的风险。
研究支持:NIH-NINDS (MRI-GENIE: R01NS086905 -πn .罗斯特K23NS064052, R01NS082285 - n .罗斯特迹象:U01 NS069208 - j . Rosand s Kittner R01NS059775, R01NS063925, R01NS082285, P50NS051343, R01NS086905, U01 NS069208 - o . Wu), NIH NIBIB (P41EB015902 - p . Golland)。
披露:Schirmer博士没有披露。Dalca博士没有披露。博士曾经没有披露。Giese博士没有披露。布罗德里克博士已经收到个人赔偿的活动与辉瑞公司担任顾问。Jimenez-Conde博士没有披露。Holmegaard博士没有披露。Kissela博士已经收到个人活动与詹森和AbbVie补偿,Inc . Kleindorfer博士已经收到和Genentech个人补偿活动。Lemmens博士没有披露。林格伦博士已经收到个人补偿活动与辉瑞和勃林格殷格翰集团科学顾问委员会和说话。 Dr. Meschia has received personal compensation in an editorial capacity for the European Journal of Neurology. Dr. Rundek has nothing to disclose. Dr. Sacco has received research support from Boehringer Ingelheim Pharmaceuticals. Dr. Schmidt has received personal compensation for activities with Pfizer, Janssen, Lundbeck, Merz, Novartis, Austroplant, GE Healthcare, and Probiodrug as speaker and advisory board. Dr. Schmidt has received research support from Merz Austria. Dr. Sharma has nothing to disclose. Dr. Slowik has nothing to disclose. Dr. Thijs has nothing to disclose. Dr. Woo has received research support from the NIH. Dr. Worrall has received personal compensation in an editorial capacity for the Neurology journal. Dr. Worrall has received royalty payments from Merritt's Neurology. Dr. Kittner has nothing to disclose. Dr. Rosand has received personal compensation for activities with Pfizer as a member of the Data Safety Monitoring Board. Dr. Wu has received (royalty or license fee or contractual rights) payments from GE, Siemens, and Olea Medical. Dr. Golland has nothing to disclose. Dr. Rost has received personal compensation for activities with Genzyme, Omniox, Broadview Ventures and CardioNet as a consult and Merck for serving on the clinical events committee. Dr. Rost has received personal compensation in an editorial capacity for Current Treatment Options in Cardiovascular Disease.
